ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
CeloNova BioSciences Introduces A New Class Of Coronary Stent: The CATANIA(TM) Coronary Stent System With NanoThin Polyzene(R)-F
CeloNova BioSciences, Inc.
("CeloNova"), leading and accelerating healthcare solutions through the
development of innovative medical devices, announced breakthrough
results from the ATLANTA study of the CATANIA(TM) Coronary Stent System
with NanoThin Polyzene(R)-F at the 20th Annual International Symposium on
Endovascular Therapy (ISET).
Corrado Tamburino, MD, President of the Italian Society of
Interventional Cardiology, Chief of Interventional Cardiology at Ferrarotto
Hospital and Full Professor of Cardiology at the University of Catania is
Principal Investigator for the ATLANTA study. Dr. Tamburino noted, "I
perform many angioplasties in each single day, many, and I am totally
impressed by the performance of this stent in a very complex patient
population. No thrombosis. Low binary restenosis. No MIs. This may be an
answer to the problems we are facing with other stent systems."
The CATANIA(TM) Stent System with NanoThin Polyzene(R)-F, dubbed "The
CAT" by cardiologists who have used the product, has completed CE Marking
and is available for sale anywhere the CE Mark is accepted. Advantages
include:
-- Early and complete vessel healing, as early as 30 days.
-- Patients can discontinue dual anti-platelet therapy after only one
month.
-- Protection from stent thrombosis
-- The Polyzene(R)-F surface treatment is bacterial-resistant
"The FDA has cautioned physicians about a small but significant
increased risk of stent thrombosis for patients with drug-eluting stents.
Now, Britain's National Institute for Health and Clinical Excellence is
considering restrictions on DES because they are not cost-effective for
most patients and because of uncertainties about safety. Polyzene(R)-F
seems to solicit a positive biological response that treats the stent as
accepted part of the vessel. As a result, 'The CAT' patients have excellent
outcomes and can be free from the medical complications and financial
burden associated with indefinite anti-platelet therapy," stated Thomas A.
Gordy, President and Chief Executive Officer.
About CeloNova BioSciences, Inc.
Headquartered in Newnan, near Atlanta, Georgia, CeloNova BioSciences,
Inc., is a developer of novel medical devices that are then enhanced by one
of the Company's proprietary materials, Polyzene(R)-F. Polyzene(R)-F is
highly lubricious, anti-inflammatory, and bacterial-resistant making it an
ideal surface treatment for implanted medical devices. The Company's
current products include its Embozene(TM) Color-Advanced Microspheres and
the CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F. Other
innovative devices are currently in the company's developmental pipeline.
For more information, please visit http://www.celonova.com.
CeloNova BioSciences, Inc.
http://www.celonova.com
CeloNova Biotehnologie introduce o nouã clasã de stent coronarian: la Catania (tm) cu sistem de stent coronarian NanoThin Polyzene (R)-F - CeloNova BioSciences Introduces A New Class Of Coronary Stent: The CATANIA(TM) Coronary Stent System With NanoThin Polyzene(R)-F - articole medicale engleza - startsanatate